Document is current
Any future updates will be listed below
-
Authors
Boeckmans, Joost https://orcid.org/0000-0001-8399-5872
Hagström, Hannes https://orcid.org/0000-0002-8474-1759
Cryer, Donna R. https://orcid.org/0000-0001-5243-7843
Schattenberg, Jörn M. https://orcid.org/0000-0002-4224-4703
- License Information
-
More Information
Article History
Received: 28 June 2024
Accepted: 16 April 2025
First Online: 1 May 2025
Competing interests
: J.B. reports research funding from Colgate-Palmolive. H.H. reports research funding from AstraZeneca, EchoSens, Gilead, Intercept, MSD, Novo Nordisk and Pfizer. He has served as a consultant for AstraZeneca and Novo Nordisk, and has been or is part of hepatic events adjudication committees for Arrowhead, Boehringer Ingelheim, KOWA and GW Pharma. D.R.C. is an employee of the Global Liver Institute, which convenes the NASH Council, has received grants and sponsorships from several companies in the NASH therapeutic space, and is an advisor to PathAI and Chronwell. J.M.S. reports consulting for Alentis, Alexion, Altimmune, Astra Zeneca, 89Bio, Bionorica, Boehringer Ingelheim, Gilead Sciences, GSK, Ipsen, Inventiva Pharma, Madrigal Pharmaceuticals, Lilly, MSD, Northsea Therapeutics, Novartis, Novo Nordisk, Pfizer, Roche, Sanofi, and Siemens Healthineers. speaker honorarium from AbbVie, Academic Medical Education (AME), Boehringer Ingelheim, Echosens, Forum für Medizinische Fortbildung (FOMF), Gilead Sciences, MedicalTribune, MedPublico GmbH, MedScape, Novo Nordisk, Madrigal Pharmaceuticals, Stockholder options: AGED diagnostics, and Hepta Bio.
